LONDONAstraZeneca PLC has agreed to buy the rights to a portfolio of inhaled drugs from Almirall SA in a deal worth up to  billion a significant step toward expanding its respiratory business and the type of pipelineboosting deal favored by Chief Executive Pascal Soriot The deal will give the UK drug maker a type of treatment for chronic obstructive pulmonary disease which it currently lacks a new type of inhaler and a portfolio of pipeline drugs potentially helping it compete better with rivals such as respiratorymarket
  